{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T22:13:33Z","timestamp":1782339213100,"version":"3.54.5"},"reference-count":26,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"<jats:sec>\n                    <jats:title>CONTEXT<\/jats:title>\n                    <jats:p>Cystic fibrosis\u2013related diabetes significantly impacts health outcomes of people with cystic fibrosis (CF). Understanding the effects of CF transmembrane conductance regulator modulator (CFTRm) therapy on glycemic control is crucial for improving overall health in CF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To evaluate the impact of CFTRm therapy on glycemic control in people with CF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES<\/jats:title>\n                    <jats:p>A comprehensive literature search was conducted from January 1, 2011, to September 19, 2024, in PubMed, Embase, and Cochrane Central Register of Controlled Trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY SELECTION<\/jats:title>\n                    <jats:p>Eligible studies included interventional trials comparing CFTRm therapy to no treatment or placebo and observational studies reporting glycemic outcomes\u2014assessed by oral glucose tolerance test or continuous glucose monitoring\u2014pretherapy and on therapy or between treated individuals and controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA EXTRACTION<\/jats:title>\n                    <jats:p>Two authors independently extracted data with full adherence to the Cochrane Handbook.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Elexacaftor\/tezacaftor\/ivacaftor therapy (ETI) significantly improved 120-minute glucose levels (mean difference, \u221224.30\u00a0mg\/dL; 95% CI, \u221244.82 to \u22123.96) and lowered hemoglobin A1c (HbA1c) levels (mean difference, \u22120.44%; 95% CI, \u22120.75 to \u22120.13). Regression analyses showed that earlier ETI therapy initiation was associated with lower HbA1c values (P\u2009=\u2009.03). In contrast, lumacaftor\/ivacaftor, tezacaftor\/ivacaftor, and ivacaftor monotherapy were not associated with significant changes in any assessed outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LIMITATIONS<\/jats:title>\n                    <jats:p>Our analyses may underestimate the endocrine effects of CFTRm therapies, as most included papers assessed pre- and on-therapy outcomes in the same patients, potentially overlooking the gradual deterioration of glycemic control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>ETI therapy significantly improves glycemic control in CF, particularly when initiated at a young age. Further research is needed to confirm and detail these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1542\/peds.2024-070328","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:02:39Z","timestamp":1769472159000},"source":"Crossref","is-referenced-by-count":1,"title":["CFTR Modulator Therapy and Glycemic Control: A Meta-Analysis"],"prefix":"10.1542","volume":"157","author":[{"given":"Szabolcs","family":"Kiss","sequence":"first","affiliation":[{"name":"1Heim P\u00e1l National Pediatric Institute, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rk F\u00e9lix","family":"Juh\u00e1sz","sequence":"additional","affiliation":[{"name":"1Heim P\u00e1l National Pediatric Institute, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"K\u00f3i","sequence":"additional","affiliation":[{"name":"2Centre for Translational Medicine, Semmelweis University, Budapest, Hungary"},{"name":"3Department of Stochastics, Institute of Mathematics, Budapest University of Technology and Economics, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klementina","family":"Ocskay","sequence":"additional","affiliation":[{"name":"1Heim P\u00e1l National Pediatric Institute, Budapest, Hungary"},{"name":"4Pharmaceutical Sciences and Health Technologies Division, Doctoral School, Semmelweis University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"P\u00e1rniczky","sequence":"additional","affiliation":[{"name":"1Heim P\u00e1l National Pediatric Institute, Budapest, Hungary"},{"name":"2Centre for Translational Medicine, Semmelweis University, Budapest, Hungary"},{"name":"3Department of Stochastics, Institute of Mathematics, Budapest University of Technology and Economics, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"issue":"3","key":"2026033105181364300_r1","doi-asserted-by":"crossref","first-page":"e220740","DOI":"10.1001\/jamanetworkopen.2022.0740","article-title":"Association of body mass index with clinical outcomes in patients with cystic fibrosis: a systematic review and meta-analysis","volume":"5","author":"Nagy","year":"2022","journal-title":"JAMA Netw Open."},{"key":"2026033105181364300_r2","first-page":"3","article-title":"Cystic fibrosis-related diabetes: clinical approach and knowledge gaps","volume":"46","author":"Prentice","year":"2023","journal-title":"Paediatr Respir Rev."},{"issue":"4","key":"2026033105181364300_r3","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jcf.2024.02.010","article-title":"Early onset of abnormal glucose tolerance in patients with cystic fibrosis: a systematic review and meta-analysis","volume":"23","author":"K\u00e9ri","year":"2024","journal-title":"J Cyst Fibros."},{"issue":"8","key":"2026033105181364300_r4","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/pedi.13453","article-title":"ISPAD Clinical Practice Consensus Guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents","volume":"23","author":"Ode","journal-title":"Pediatr Diabetes."},{"issue":"1","key":"2026033105181364300_r5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-med-042921-021447","article-title":"Cystic fibrosis modulator therapies","volume":"74","author":"Jia","year":"2023","journal-title":"Annu Rev Med."},{"issue":"1","key":"2026033105181364300_r6","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/s41598-025-86010-1","article-title":"Body composition changes and clinical outcomes in pediatric cystic fibrosis during 24\u00a0months of lumacaftor ivacaftor therapy based on real-world data","volume":"15","author":"Imrei","year":"2025","journal-title":"Sci Rep."},{"issue":"71","key":"2026033105181364300_r7","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"issue":"3","key":"2026033105181364300_r8","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med (Zagreb)."},{"issue":"4","key":"2026033105181364300_r9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/jrsm.1563","article-title":"citationchaser: an R package and Shiny app for forward and backward citations chasing in academic searching","volume":"13","author":"Haddaway","year":"2022","journal-title":"Res Synth Methods."},{"issue":"8","key":"2026033105181364300_r10","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care."},{"issue":"3","key":"2026033105181364300_r11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.11124\/JBIES-22-00224","article-title":"Assessing the risk of bias of quantitative analytical studies: introducing the vision for critical appraisal within JBI systematic reviews","volume":"21","author":"Munn","year":"2023","journal-title":"JBI Evid Synth."},{"key":"2026033105181364300_r12","doi-asserted-by":"crossref","DOI":"10.1201\/9781003107347","volume-title":"Doing Meta-Analysis With R: A Hands-On Guide","author":"Harrer","year":"2021"},{"issue":"2","key":"2026033105181364300_r13","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/jrsm.1474","article-title":"Handbook of meta-analysis","volume":"12","author":"R\u00fccker","year":"2021","journal-title":"Res Synth Methods."},{"key":"2026033105181364300_r14","article-title":"Assessing the properties of the prediction interval in random-effects meta-analysis","volume-title":"arXiv.","author":"P\u00e9ter","year":"2024"},{"key":"2026033105181364300_r15","first-page":"100332","article-title":"The changing landscape of treatment for cystic fibrosis related diabetes","volume":"35","author":"Amini","year":"2024","journal-title":"J Clin Transl Endocrinol."},{"issue":"suppl 1","key":"2026033105181364300_r16","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/S1569-1993(15)30305-2","article-title":"128 The metabolic consequences of CFTR modulation with ivacaftor in a single adult cystic fibrosis centre cohort","volume":"14","author":"Ronan","year":"2015","journal-title":"J Cyst Fibros."},{"issue":"suppl 2","key":"2026033105181364300_r17","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S1569-1993(23)00338-7","article-title":"EPS5.08 Elexacaftor\/tezacaftor\/ivacaftor reduces need for pancreatic enzymes, enteral feeding and omeprazole use without causing excessive weight gain: a 2-year observational study","volume":"22","author":"Scanlan","year":"2023","journal-title":"J Cyst Fibros."},{"issue":"7","key":"2026033105181364300_r18","first-page":"e41697","article-title":"The effects of elexacaftor, tezacaftor, and ivacaftor (ETI) on blood glucose in patients with cystic fibrosis: a systematic review","volume":"15","author":"Salazar-Barragan","year":"2023","journal-title":"Cureus."},{"key":"2026033105181364300_r19","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions (version 6.5)","author":"Higgins","year":"2024"},{"issue":"suppl 1","key":"2026033105181364300_r20","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.jcf.2022.12.017","article-title":"CFTR-beyond the airways: recent findings on the role of the CFTR channel in the pancreas, the intestine and the kidneys","volume":"22","author":"Hegyi","year":"2023","journal-title":"J Cyst Fibros."},{"issue":"10","key":"2026033105181364300_r21","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1210\/en.2017-00187","article-title":"CFTR influences beta cell function and insulin secretion through non-cell autonomous exocrine-derived factors","volume":"158","author":"Sun","year":"2017","journal-title":"Endocrinology."},{"issue":"10","key":"2026033105181364300_r22","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1210\/clinem\/dgaa448","article-title":"Hypoglycemia and islet dysfunction following oral glucose tolerance testing in pancreatic-insufficient cystic fibrosis","volume":"105","author":"Kilberg","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"key":"2026033105181364300_r23","doi-asserted-by":"crossref","first-page":"852551","DOI":"10.3389\/fped.2022.852551","article-title":"Short-term effects of elexacaftor\/tezacaftor\/ivacaftor combination on glucose tolerance in young people with cystic fibrosis-an observational pilot study","volume":"10","author":"Korten","year":"2022","journal-title":"Front Pediatr."},{"issue":"4","key":"2026033105181364300_r24","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jcf.2023.01.004","article-title":"improved glucose tolerance after initiation of Elexacaftor\/Tezacaftor\/Ivacaftor in adults with cystic fibrosis","volume":"22","author":"Steinack","year":"2023","journal-title":"J Cyst Fibros."},{"key":"2026033105181364300_r25","doi-asserted-by":"crossref","first-page":"1157459","DOI":"10.3389\/fphar.2023.1157459","article-title":"Weight increase in people with cystic fibrosis on CFTR modulator therapy is mainly due to increase in fat mass","volume":"14","author":"Mouzaki","year":"2023","journal-title":"Front Pharmacol."},{"key":"2026033105181364300_r26","doi-asserted-by":"crossref","first-page":"630654","DOI":"10.3389\/fcell.2021.630654","article-title":"CFTR deficiency affects glucose homeostasis via regulating GLUT4 plasma membrane transportation","volume":"9","author":"Gu","year":"2021","journal-title":"Front Cell Dev Biol."}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2024-070328\/1908008\/pediatrics.2024070328.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2024-070328\/1908008\/pediatrics.2024070328.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:18:21Z","timestamp":1774948701000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/157\/2\/e2024070328\/206162\/CFTR-Modulator-Therapy-and-Glycemic-Control-A-Meta"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1,27]]},"published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2024-070328","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"article-number":"e2024070328"}}